Doo Ryeon Chung

Chief / Professor

Samsung Medical Center

South Korea

Research Interests

Explore related searches

Professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Doo Ryeon Chung is a Chief Professor at Samsung Medical Center in South Korea. His research primarily focuses on infectious diseases, including clinical outcomes of tuberculosis treatments in solid organ transplant recipients, antibiotic resistance mechanisms, and immune responses to SARS-CoV-2. He has contributed to various studies on antibiotic therapies and public health implications following the COVID-19 pandemic.

Articles (13)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

SOUTH KOREA

View details

Si-Ho Kim

assistant professor

Kangbuk Samsung Hospital

SOUTH KOREA

View details

Kyong Ran Peck

Professor

Samsung Medical Center

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Doo Ryeon Chung

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Synergistic effects of colistin–rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay

Clinical Outcome of Rifabutin-Based Treatment for Pulmonary Tuberculosis in Solid Organ Transplant Recipients

Augmented humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 after breakthrough infection in kidney transplant recipients who received 3 doses of coronavirus disease 2019 vaccine

Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review

Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023

Retraction for Shin et al., “ bla NDM-5 -Bearing IncFII-Type Plasmids of Klebsiella pneumoniae Sequence Type 147 Transmitted by Cross-Border Transfer of a Patient”

Genetic alterations in methicillin-susceptible Staphylococcus aureus associated with high vancomycin minimum inhibitory concentration

False-positive Aspergillus galactomannan immunoassay in the glucose component of total parenteral nutrition products

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia

Public interest in the digital transformation accelerated by the COVID-19 pandemic and perception of its future impact

Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19

Responses against infectious disease pandemics: a narrative review on COVID-19

Collaborators (7)

Kwan Soo Ko

Cheol-In Kang

Jae-Hoon Ko

Kyungmin Huh

Seongman Bae

Si-Ho Kim

Kyong Ran Peck

Make your next move.